Tardive Dyskinesia Treatment Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Disorder (Bradykinesia, Hyperkinesia); Drug Class (Dopamine-Depleting Medications, VMAT2 Inhibitors, GABA Receptor Agonist Medications, Anticholinergic Medications Trihexyphenidyl); End User (Hospitals, Clinical, Others) and Geography

Report Code: TIPRE00021909 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!
MARKET INTRODUCTION

Tardive Dyskinesia treatment is result of side effects of antipsychotic drugs. These types of drugs are used to treat mental disorders such as schizophrenia and others. Involuntary muscle movements are symptoms of Tardive Dyskinesia. The treatment of the disorder includes inhibiting the use of drugs causing and aggravating the disorder.

MARKET DYNAMICS

The Tardive Dyskinesia treatment market is driving due to the rise in population with neurological disorders . However, lack of diagnosis of Tardive Dyskinesia treatment are expected to hamper the growth of the global Tardive Dyskinesia treatment market.

MARKET SCOPE

The "Tardive Dyskinesia Treatment Market Analysis to 2027" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of Tardive Dyskinesia Treatment market with detailed market segmentation by disorder and drug class and end user. The Tardive Dyskinesia Treatment market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in Tardive Dyskinesia Treatment market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The Tardive Dyskinesia treatment market is segmented on the basis of disorder, drug class and end user. Based on disorder, the market is segmented as Bradykinesia, Hyperkinesia. On the basis of drug class, the market is categorized as Dopamine-Depleting Medications, VMAT2 Inhibitors, GABA Receptor Agonist Medications and Anticholinergic Medications Trihexyphenidyl. On the basis of end user, the market is categorized as Hospitals, Clinical and others

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Tardive Dyskinesia Treatment market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Tardive Dyskinesia Treatment market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Tardive Dyskinesia Treatment market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Tardive Dyskinesia Treatment market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the Tardive Dyskinesia Treatment market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Tardive Dyskinesia Treatment market are anticipated to have lucrative growth opportunities in the future with the rising demand for Tardive Dyskinesia Treatment in the global market. Below mentioned is the list of few companies engaged in the Tardive Dyskinesia Treatment market.

The report also includes the profiles of key players in Tardive Dyskinesia Treatment market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •   Teva Pharmaceutical Industries Ltd
  •   Neurocrine Biosciences, Inc
  •   Sun Pharmaceutical Industries Ltd
  •   SteriMax Inc.
  •   Adamas Pharmaceuticals, Inc
  •   Sanis
  •   AbbVie Inc.
  •   Mylan N.V,
  •   Reddy's Laboratories Ltd,
  •   Sun Pharmaceutical Industries Ltd

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Tardive Dyskinesia Treatment Market - By Disorder
1.3.2 Tardive Dyskinesia Treatment Market - By Drug Class
1.3.3 Tardive Dyskinesia Treatment Market - By End User
1.3.4 Tardive Dyskinesia Treatment Market - By Region
1.3.4.1 By Country

2. KEY TAKEAWAYS

3. RESEARCH METHODOLOGY

4. TARDIVE DYSKINESIA TREATMENT MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS

5. TARDIVE DYSKINESIA TREATMENT MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS

6. TARDIVE DYSKINESIA TREATMENT MARKET - GLOBAL MARKET ANALYSIS
6.1. TARDIVE DYSKINESIA TREATMENT - GLOBAL MARKET OVERVIEW
6.2. TARDIVE DYSKINESIA TREATMENT - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING

7. TARDIVE DYSKINESIA TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - DISORDER
7.1. OVERVIEW
7.2. DISORDER MARKET FORECASTS AND ANALYSIS
7.3. BRADYKINESIA
7.3.1. Overview
7.3.2. Bradykinesia Market Forecast and Analysis
7.4. HYPERKINESIA
7.4.1. Overview
7.4.2. Hyperkinesia Market Forecast and Analysis
8. TARDIVE DYSKINESIA TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASS
8.1. OVERVIEW
8.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
8.3. DOPAMINE-DEPLETING MEDICATIONS
8.3.1. Overview
8.3.2. Dopamine-Depleting Medications Market Forecast and Analysis
8.4. VMAT2 INHIBITORS
8.4.1. Overview
8.4.2. VMAT2 Inhibitors Market Forecast and Analysis
8.5. GABA RECEPTOR AGONIST MEDICATIONS
8.5.1. Overview
8.5.2. GABA Receptor Agonist Medications Market Forecast and Analysis
8.6. ANTICHOLINERGIC MEDICATIONS TRIHEXYPHENIDYL
8.6.1. Overview
8.6.2. Anticholinergic Medications Trihexyphenidyl Market Forecast and Analysis
9. TARDIVE DYSKINESIA TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - END USER
9.1. OVERVIEW
9.2. END USER MARKET FORECASTS AND ANALYSIS
9.3. HOSPITALS
9.3.1. Overview
9.3.2. Hospitals Market Forecast and Analysis
9.4. CLINICAL
9.4.1. Overview
9.4.2. Clinical Market Forecast and Analysis
9.5. OTHERS
9.5.1. Overview
9.5.2. Others Market Forecast and Analysis

10. TARDIVE DYSKINESIA TREATMENT MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Tardive Dyskinesia Treatment Market Overview
10.1.2 North America Tardive Dyskinesia Treatment Market Forecasts and Analysis
10.1.3 North America Tardive Dyskinesia Treatment Market Forecasts and Analysis - By Disorder
10.1.4 North America Tardive Dyskinesia Treatment Market Forecasts and Analysis - By Drug Class
10.1.5 North America Tardive Dyskinesia Treatment Market Forecasts and Analysis - By End User
10.1.6 North America Tardive Dyskinesia Treatment Market Forecasts and Analysis - By Countries
10.1.6.1 United States Tardive Dyskinesia Treatment Market
10.1.6.1.1 United States Tardive Dyskinesia Treatment Market by Disorder
10.1.6.1.2 United States Tardive Dyskinesia Treatment Market by Drug Class
10.1.6.1.3 United States Tardive Dyskinesia Treatment Market by End User
10.1.6.2 Canada Tardive Dyskinesia Treatment Market
10.1.6.2.1 Canada Tardive Dyskinesia Treatment Market by Disorder
10.1.6.2.2 Canada Tardive Dyskinesia Treatment Market by Drug Class
10.1.6.2.3 Canada Tardive Dyskinesia Treatment Market by End User
10.1.6.3 Mexico Tardive Dyskinesia Treatment Market
10.1.6.3.1 Mexico Tardive Dyskinesia Treatment Market by Disorder
10.1.6.3.2 Mexico Tardive Dyskinesia Treatment Market by Drug Class
10.1.6.3.3 Mexico Tardive Dyskinesia Treatment Market by End User
10.2. EUROPE
10.2.1 Europe Tardive Dyskinesia Treatment Market Overview
10.2.2 Europe Tardive Dyskinesia Treatment Market Forecasts and Analysis
10.2.3 Europe Tardive Dyskinesia Treatment Market Forecasts and Analysis - By Disorder
10.2.4 Europe Tardive Dyskinesia Treatment Market Forecasts and Analysis - By Drug Class
10.2.5 Europe Tardive Dyskinesia Treatment Market Forecasts and Analysis - By End User
10.2.6 Europe Tardive Dyskinesia Treatment Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Tardive Dyskinesia Treatment Market
10.2.6.1.1 Germany Tardive Dyskinesia Treatment Market by Disorder
10.2.6.1.2 Germany Tardive Dyskinesia Treatment Market by Drug Class
10.2.6.1.3 Germany Tardive Dyskinesia Treatment Market by End User
10.2.6.2 France Tardive Dyskinesia Treatment Market
10.2.6.2.1 France Tardive Dyskinesia Treatment Market by Disorder
10.2.6.2.2 France Tardive Dyskinesia Treatment Market by Drug Class
10.2.6.2.3 France Tardive Dyskinesia Treatment Market by End User
10.2.6.3 Italy Tardive Dyskinesia Treatment Market
10.2.6.3.1 Italy Tardive Dyskinesia Treatment Market by Disorder
10.2.6.3.2 Italy Tardive Dyskinesia Treatment Market by Drug Class
10.2.6.3.3 Italy Tardive Dyskinesia Treatment Market by End User
10.2.6.4 Spain Tardive Dyskinesia Treatment Market
10.2.6.4.1 Spain Tardive Dyskinesia Treatment Market by Disorder
10.2.6.4.2 Spain Tardive Dyskinesia Treatment Market by Drug Class
10.2.6.4.3 Spain Tardive Dyskinesia Treatment Market by End User
10.2.6.5 United Kingdom Tardive Dyskinesia Treatment Market
10.2.6.5.1 United Kingdom Tardive Dyskinesia Treatment Market by Disorder
10.2.6.5.2 United Kingdom Tardive Dyskinesia Treatment Market by Drug Class
10.2.6.5.3 United Kingdom Tardive Dyskinesia Treatment Market by End User
10.2.6.6 Rest of Europe Tardive Dyskinesia Treatment Market
10.2.6.6.1 Rest of Europe Tardive Dyskinesia Treatment Market by Disorder
10.2.6.6.2 Rest of Europe Tardive Dyskinesia Treatment Market by Drug Class
10.2.6.6.3 Rest of Europe Tardive Dyskinesia Treatment Market by End User
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Tardive Dyskinesia Treatment Market Overview
10.3.2 Asia-Pacific Tardive Dyskinesia Treatment Market Forecasts and Analysis
10.3.3 Asia-Pacific Tardive Dyskinesia Treatment Market Forecasts and Analysis - By Disorder
10.3.4 Asia-Pacific Tardive Dyskinesia Treatment Market Forecasts and Analysis - By Drug Class
10.3.5 Asia-Pacific Tardive Dyskinesia Treatment Market Forecasts and Analysis - By End User
10.3.6 Asia-Pacific Tardive Dyskinesia Treatment Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Tardive Dyskinesia Treatment Market
10.3.6.1.1 Australia Tardive Dyskinesia Treatment Market by Disorder
10.3.6.1.2 Australia Tardive Dyskinesia Treatment Market by Drug Class
10.3.6.1.3 Australia Tardive Dyskinesia Treatment Market by End User
10.3.6.2 China Tardive Dyskinesia Treatment Market
10.3.6.2.1 China Tardive Dyskinesia Treatment Market by Disorder
10.3.6.2.2 China Tardive Dyskinesia Treatment Market by Drug Class
10.3.6.2.3 China Tardive Dyskinesia Treatment Market by End User
10.3.6.3 India Tardive Dyskinesia Treatment Market
10.3.6.3.1 India Tardive Dyskinesia Treatment Market by Disorder
10.3.6.3.2 India Tardive Dyskinesia Treatment Market by Drug Class
10.3.6.3.3 India Tardive Dyskinesia Treatment Market by End User
10.3.6.4 Japan Tardive Dyskinesia Treatment Market
10.3.6.4.1 Japan Tardive Dyskinesia Treatment Market by Disorder
10.3.6.4.2 Japan Tardive Dyskinesia Treatment Market by Drug Class
10.3.6.4.3 Japan Tardive Dyskinesia Treatment Market by End User
10.3.6.5 South Korea Tardive Dyskinesia Treatment Market
10.3.6.5.1 South Korea Tardive Dyskinesia Treatment Market by Disorder
10.3.6.5.2 South Korea Tardive Dyskinesia Treatment Market by Drug Class
10.3.6.5.3 South Korea Tardive Dyskinesia Treatment Market by End User
10.3.6.6 Rest of Asia-Pacific Tardive Dyskinesia Treatment Market
10.3.6.6.1 Rest of Asia-Pacific Tardive Dyskinesia Treatment Market by Disorder
10.3.6.6.2 Rest of Asia-Pacific Tardive Dyskinesia Treatment Market by Drug Class
10.3.6.6.3 Rest of Asia-Pacific Tardive Dyskinesia Treatment Market by End User
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Tardive Dyskinesia Treatment Market Overview
10.4.2 Middle East and Africa Tardive Dyskinesia Treatment Market Forecasts and Analysis
10.4.3 Middle East and Africa Tardive Dyskinesia Treatment Market Forecasts and Analysis - By Disorder
10.4.4 Middle East and Africa Tardive Dyskinesia Treatment Market Forecasts and Analysis - By Drug Class
10.4.5 Middle East and Africa Tardive Dyskinesia Treatment Market Forecasts and Analysis - By End User
10.4.6 Middle East and Africa Tardive Dyskinesia Treatment Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Tardive Dyskinesia Treatment Market
10.4.6.1.1 South Africa Tardive Dyskinesia Treatment Market by Disorder
10.4.6.1.2 South Africa Tardive Dyskinesia Treatment Market by Drug Class
10.4.6.1.3 South Africa Tardive Dyskinesia Treatment Market by End User
10.4.6.2 Saudi Arabia Tardive Dyskinesia Treatment Market
10.4.6.2.1 Saudi Arabia Tardive Dyskinesia Treatment Market by Disorder
10.4.6.2.2 Saudi Arabia Tardive Dyskinesia Treatment Market by Drug Class
10.4.6.2.3 Saudi Arabia Tardive Dyskinesia Treatment Market by End User
10.4.6.3 U.A.E Tardive Dyskinesia Treatment Market
10.4.6.3.1 U.A.E Tardive Dyskinesia Treatment Market by Disorder
10.4.6.3.2 U.A.E Tardive Dyskinesia Treatment Market by Drug Class
10.4.6.3.3 U.A.E Tardive Dyskinesia Treatment Market by End User
10.4.6.4 Rest of Middle East and Africa Tardive Dyskinesia Treatment Market
10.4.6.4.1 Rest of Middle East and Africa Tardive Dyskinesia Treatment Market by Disorder
10.4.6.4.2 Rest of Middle East and Africa Tardive Dyskinesia Treatment Market by Drug Class
10.4.6.4.3 Rest of Middle East and Africa Tardive Dyskinesia Treatment Market by End User
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Tardive Dyskinesia Treatment Market Overview
10.5.2 South and Central America Tardive Dyskinesia Treatment Market Forecasts and Analysis
10.5.3 South and Central America Tardive Dyskinesia Treatment Market Forecasts and Analysis - By Disorder
10.5.4 South and Central America Tardive Dyskinesia Treatment Market Forecasts and Analysis - By Drug Class
10.5.5 South and Central America Tardive Dyskinesia Treatment Market Forecasts and Analysis - By End User
10.5.6 South and Central America Tardive Dyskinesia Treatment Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Tardive Dyskinesia Treatment Market
10.5.6.1.1 Brazil Tardive Dyskinesia Treatment Market by Disorder
10.5.6.1.2 Brazil Tardive Dyskinesia Treatment Market by Drug Class
10.5.6.1.3 Brazil Tardive Dyskinesia Treatment Market by End User
10.5.6.2 Argentina Tardive Dyskinesia Treatment Market
10.5.6.2.1 Argentina Tardive Dyskinesia Treatment Market by Disorder
10.5.6.2.2 Argentina Tardive Dyskinesia Treatment Market by Drug Class
10.5.6.2.3 Argentina Tardive Dyskinesia Treatment Market by End User
10.5.6.3 Rest of South and Central America Tardive Dyskinesia Treatment Market
10.5.6.3.1 Rest of South and Central America Tardive Dyskinesia Treatment Market by Disorder
10.5.6.3.2 Rest of South and Central America Tardive Dyskinesia Treatment Market by Drug Class
10.5.6.3.3 Rest of South and Central America Tardive Dyskinesia Treatment Market by End User

11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

12. TARDIVE DYSKINESIA TREATMENT MARKET, KEY COMPANY PROFILES
12.1. TEVA PHARMACEUTICAL INDUSTRIES LTD
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. NEUROCRINE BIOSCIENCES, INC
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. SUN PHARMACEUTICAL INDUSTRIES LTD
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. STERIMAX INC.
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. ADAMAS PHARMACEUTICALS, INC
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. SANIS
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. ABBVIE INC.
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. MYLAN N.V,
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. REDDY’S LABORATORIES LTD,
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. SUN PHARMACEUTICAL INDUSTRIES LTD
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments

13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. Teva Pharmaceutical Industries Ltd
2. Neurocrine Biosciences, Inc
3. Sun Pharmaceutical Industries Ltd
4. SteriMax Inc.
5. Adamas Pharmaceuticals, Inc
6. Sanis
7. AbbVie Inc.
8. Mylan N.V,
9. Reddy’s Laboratories Ltd,
10. Sun Pharmaceutical Industries Ltd
TIPRE00021909
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking